Innovative Research Award
Yang Jilong
Tianjin Medical University Cancer Hospital,China
Yang Jilong is a Chinese oncology researcher, clinician-scientist, and academic leader specializing in bone and soft tissue oncology, melanoma, sarcoma biology, and translational precision medicine. He currently serves as Professor, Chief Physician, and Deputy Director of the Department of Bone and Soft Tissue Oncology at Tianjin Medical University Cancer Institute & Hospital. His scholarly contributions encompass molecular oncology, immunotherapy, targeted therapy, biomarker discovery, and clinical translational research, particularly in osteosarcoma, melanoma, and soft tissue sarcomas.[1]
Abstract
Yang Jilong has established a distinguished academic and clinical career in the field of oncology, with particular emphasis on sarcoma precision medicine, melanoma immunotherapy, molecular pathology, and translational cancer research. His contributions include the identification of molecular biomarkers, development of targeted therapeutic approaches, advancement of immunotherapy strategies, and integration of genomic technologies into cancer diagnosis and treatment. Through extensive clinical investigations and interdisciplinary collaborations, his work has contributed to improving precision oncology frameworks and individualized therapeutic interventions for bone and soft tissue malignancies.[2]
Keywords
Sarcoma; Melanoma; Precision Oncology; Osteosarcoma; Immunotherapy; Molecular Oncology; Bone Tumors; Soft Tissue Oncology; Translational Medicine; Tumor Microenvironment; Biomarkers; Cancer Genomics; Clinical Oncology; Personalized Medicine.
Introduction
The advancement of precision oncology has transformed the management of aggressive malignancies such as sarcomas and melanomas. Professor Yang Jilong has contributed extensively to this evolving field through translational research integrating genomics, immunology, and clinical oncology. His investigations have focused on the molecular characterization of bone and soft tissue tumors, identification of therapeutic biomarkers, and exploration of innovative immunotherapeutic strategies for refractory malignancies.[3]
Research Profile
Yang Jilong is a distinguished oncology specialist and translational cancer researcher at Tianjin Medical University Cancer Institute & Hospital. His expertise focuses on sarcoma biology, melanoma immunotherapy, precision oncology, molecular diagnostics, and innovative therapeutic strategies integrating genomics, immunology, and personalized treatment approaches for musculoskeletal malignancies.[5]
Research Contributions
Professor Yang Jilong has contributed significantly to sarcoma precision medicine, melanoma immunotherapy, molecular oncology, targeted therapeutics, and translational cancer research through innovative clinical studies, biomarker discovery, genomic investigations, and multidisciplinary treatment strategies improving oncology outcomes.
Publications
Yang has authored and co-authored more than seventy peer-reviewed scientific publications in internationally recognized journals including Advanced Science, Nature Communications, Genome Biology, Cancer Biology & Medicine, Frontiers in Oncology, and Cancer Letters. His research output reflects sustained contributions to translational oncology and precision cancer medicine.[2]
- Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. Advanced Science, 2026.
- A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. Nature Communications, 2022.
- IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Letters, 2020.
- Mesenchymal to epithelial transition in sarcomas. European Journal of Cancer, 2014.
- Genetic amplification of VEGFA pathway genes in osteosarcoma. Cancer, 2011.
Research Impact
The research contributions of Yang have influenced both clinical oncology practice and translational cancer research. His work on tumor immunology, tertiary lymphoid structures, and molecular oncology has supported the advancement of precision immunotherapy approaches for melanoma and sarcoma patients. Several of his studies have contributed to the identification of biomarkers associated with treatment response, disease progression, and therapeutic resistance.[3]
Award Suitability
Yang Jilong’s distinguished achievements in sarcoma precision oncology, translational melanoma research, immunotherapy innovation, molecular oncology, and multidisciplinary clinical leadership demonstrate exceptional scientific excellence. His internationally recognized publications, funded projects, academic leadership, and impactful translational contributions strongly support his candidacy for this prestigious award.
Concluion
Yang Jilong has established an influential academic and clinical career through pioneering sarcoma research, innovative translational oncology contributions, multidisciplinary leadership, and internationally recognized publications that continue advancing precision cancer diagnosis, treatment, and patient care.
External Links
References
- Tianjin Medical University Cancer Institute & Hospital. (2026). Professional profile of Professor Yang Jilong.
- Wang Z, Liu H, Wang X, et al. (2026). Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. Advanced Science.
https://doi.org/10.1002/advs.202515158
- Zhang C, Shen H, Yang T, et al. (2022). A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. Nature Communications.
https://www.nature.com/articles/s41467-022-34937-1
- Li T, Zhang C, Zhao G, et al. (2020). IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Letters.
https://doi.org/10.1016/j.canlet.2020.01.015
- Yang J, Yang D, Sun Y, et al. (2011). Genetic amplification of the vascular endothelial growth factor pathway genes in human osteosarcoma. Cancer.
https://doi.org/10.1002/cncr.26121